NanoBio Licenses RSV Vaccine Tech

Ann Arbor, MI-based NanoBio today announced it has licensed an antigen from the National Institutes of Health (NIH) that it says represents a significant step forward in the development of a vaccine for respiratory syncytial virus (RSV). Currently, there are no approved vaccines for RSV, an infection that sends 75,000 to 125,000 infants under 1 to the hospital each year in the United States. The agreement provides NanoBio with global rights to NIH’s new RSV antigen, which the Ann Arbor company will incorporate into a nose spray vaccine, using its proprietary oil-and-water nano-emulsion technology.

Author: Sarah Schmid Stevenson

Sarah is a former Xconomy editor. Prior to joining Xconomy in 2011, she did communications work for the Michigan Economic Development Corporation and the Michigan House of Representatives. She has also worked as a reporter and copy editor at the Missoula Independent and the Lansing State Journal. She holds a bachelor's degree in Journalism and Native American Studies from the University of Montana and proudly calls Detroit "the most fascinating city I've ever lived in."